EA201690754A1 - Применение ингибитора pcsk9 для лечения гиперлипидемии - Google Patents

Применение ингибитора pcsk9 для лечения гиперлипидемии

Info

Publication number
EA201690754A1
EA201690754A1 EA201690754A EA201690754A EA201690754A1 EA 201690754 A1 EA201690754 A1 EA 201690754A1 EA 201690754 A EA201690754 A EA 201690754A EA 201690754 A EA201690754 A EA 201690754A EA 201690754 A1 EA201690754 A1 EA 201690754A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pcsk9 inhibitor
hyperlipidemia
treatment
application
pcsk9
Prior art date
Application number
EA201690754A
Other languages
English (en)
Other versions
EA037526B1 (ru
Inventor
Мари Баккара-Дине
Лоранс Бессак
Умеш Чаудхари
Коринн Анотэн
Роберт К. Порди
Уилльям Дж. Сасьела
Дэниел А. Швеммер Гайп
Original Assignee
Санофи Байотекнолоджи
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи Байотекнолоджи, Ридженерон Фармасьютикалз, Инк. filed Critical Санофи Байотекнолоджи
Publication of EA201690754A1 publication Critical patent/EA201690754A1/ru
Publication of EA037526B1 publication Critical patent/EA037526B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)

Abstract

Настоящее изобретение относится к способам лечения гиперлипидемии у пациентов, которые не получают терапию статинами. Способы по настоящему изобретению включают введение пациенту фармацевтической композиции, содержащей ингибитор PCSK9. В определенных вариантах осуществления ингибитор PCSK9 представляет собой антитело против PCSK9, такое как иллюстративное антитело, обозначаемое в настоящем описании как mAb316Р.
EA201690754A 2013-10-11 2014-10-10 Применение ингибитора pcsk9 для лечения гиперлипидемии EA037526B1 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US201462025104P 2014-07-16 2014-07-16
EP14306221 2014-07-31
US201462054571P 2014-09-24 2014-09-24
EP14306584 2014-10-09
PCT/US2014/060109 WO2015054619A2 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia

Publications (2)

Publication Number Publication Date
EA201690754A1 true EA201690754A1 (ru) 2016-10-31
EA037526B1 EA037526B1 (ru) 2021-04-08

Family

ID=52813751

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690754A EA037526B1 (ru) 2013-10-11 2014-10-10 Применение ингибитора pcsk9 для лечения гиперлипидемии

Country Status (14)

Country Link
US (1) US20150140002A1 (ru)
EP (2) EP3055333B1 (ru)
JP (2) JP6846931B2 (ru)
KR (3) KR20230119045A (ru)
CN (3) CN115192704A (ru)
AU (2) AU2014331754B2 (ru)
CA (1) CA2926942A1 (ru)
EA (1) EA037526B1 (ru)
ES (1) ES2914978T3 (ru)
IL (1) IL244995B (ru)
MX (3) MX2016004580A (ru)
PL (2) PL3055333T4 (ru)
TW (1) TWI669131B (ru)
WO (1) WO2015054619A2 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2012101253A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN111789944A (zh) 2011-09-16 2020-10-20 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
JP6616298B2 (ja) 2013-11-12 2019-12-04 サノフィ・バイオテクノロジー Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
EP3169710A1 (en) * 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
KR20170029613A (ko) 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
CN107635512A (zh) * 2015-04-15 2018-01-26 康斯瓦维有限责任公司 用于抑制天然心脏瓣膜、被支撑的心脏瓣膜或生物假体的狭窄、阻塞或钙化的装置和方法
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
MA42657A (fr) * 2015-08-18 2018-06-27 Regeneron Pharma Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
US11111313B2 (en) 2016-09-20 2021-09-07 WuXi Biologics Ireland Limited Anti-PCSK9 antibodies
WO2018189705A1 (en) 2017-04-13 2018-10-18 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
US20200131576A1 (en) 2017-04-25 2020-04-30 The Brigham And Women's Hospital, Inc. IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis
CN107090474A (zh) * 2017-05-22 2017-08-25 山东大学 一种腹主动脉瘤疾病动物模型的制备方法
CN109963877B (zh) * 2017-06-14 2023-01-20 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
KR20200129127A (ko) * 2018-03-06 2020-11-17 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 심혈관 위험을 감소시키기 위한 pcsk9 억제제의 용도
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
KR20220107210A (ko) * 2019-11-18 2022-08-02 에이디 파마슈티컬스 컴퍼니 리미티드 항-pcsk9 항체 및 그의 용도
WO2021119321A1 (en) * 2019-12-10 2021-06-17 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
CN114277032A (zh) * 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2012101253A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN111789944A (zh) * 2011-09-16 2020-10-20 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

Also Published As

Publication number Publication date
EP3689913B1 (en) 2022-03-23
WO2015054619A3 (en) 2015-06-04
KR20220048051A (ko) 2022-04-19
AU2014331754B2 (en) 2020-06-18
WO2015054619A8 (en) 2016-03-31
AU2020203636B2 (en) 2023-05-18
CN115192704A (zh) 2022-10-18
IL244995B (en) 2019-12-31
CN115154599A (zh) 2022-10-11
EP3055333B1 (en) 2019-12-04
CN105814085A (zh) 2016-07-27
PL3689913T3 (pl) 2022-07-04
AU2014331754A1 (en) 2016-05-26
CA2926942A1 (en) 2015-04-16
MX2020004023A (es) 2020-08-13
AU2020203636A1 (en) 2020-06-25
EP3689913A1 (en) 2020-08-05
MX2022013172A (es) 2022-11-30
IL244995A0 (en) 2016-05-31
MX2016004580A (es) 2016-12-08
WO2015054619A2 (en) 2015-04-16
PL3055333T4 (pl) 2020-07-27
EA037526B1 (ru) 2021-04-08
KR20160062166A (ko) 2016-06-01
PL3055333T3 (pl) 2020-06-01
TWI669131B (zh) 2019-08-21
ES2914978T3 (es) 2022-06-20
EP3055333A2 (en) 2016-08-17
JP6994484B2 (ja) 2022-02-04
KR20230119045A (ko) 2023-08-14
JP2019214594A (ja) 2019-12-19
JP2016538248A (ja) 2016-12-08
TW201605475A (zh) 2016-02-16
US20150140002A1 (en) 2015-05-21
JP6846931B2 (ja) 2021-03-24

Similar Documents

Publication Publication Date Title
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
EA201991484A1 (ru) Лекарственные формы энзалутамида
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
PH12016502355A1 (en) Pharmaceutical composition
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
BR112014016805A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
EA201590332A1 (ru) Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
PH12016502352A1 (en) Pharmaceutical composition
EA201491500A1 (ru) Способы лечения фиброза
TW201613578A (en) Pharmaceutical combinations
EA201491875A1 (ru) Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201490495A1 (ru) Новые легкоразрушающиеся ингибиторы rock
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона